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Original Article
Reporting of placebo medication
descriptors in randomised controlled
trials: A review of three medical journals
Michelle Watson , Catherine Arundel, Laura Clark ,
Liz Cook and Illary Sbizzera
Abstract
Clinical trials involving a placebo enable researchers to determine the effectiveness of a product; however, ensuring a
placebo matches an active treatment takes great consideration, time and costs. We aimed to assess the reporting quality
of blinding descriptions for placebo medication treatments and consider this in relation to funding support (commercial
or non-commercial). The Journal of the American Medical Association (JAMA); the Lancet and the New England Journal
of Medicine (NEJM) were searched for randomised clinical trials, and 117 papers involving a placebo medication,
published between 1 April 2016 and 31 March 2017, were extracted. The data were analysed for the number of
publications reporting characteristics of placebo treatments, frequency of the characteristics and source of funding.
Three quarters of the articles reported at least one characteristic of the placebo. The Lancet and JAMA consistently had
this information present; however, this was observed less in the NEJM. The most common characteristic was ‘matching
placebo’, followed by contents of the placebo, packaging and appearance. Texture, taste and smell were least reported.
Within those supported by commercial funding, two-thirds reported at least one characteristic of the placebo treat-
ment, whilst almost all of the articles without commercial funding reported at least one characteristic. Efforts are being
made to include descriptions of blinded medication; however, inconsistencies suggest that guidelines are not always
being followed, and more can be done to improve reporting. Future research should focus on the reasons for inadequate
recording and aim to reduce the inconsistencies observed.
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Introduction
Clinical trials are planned experiments that enable
researchers to investigate the effect of an intervention
on an outcome, based on the responses from a group of
participants’ representative of the target population.
Blinded randomised controlled trials are considered
to be the gold standard of research.1 In a double-
blind trial, neither the investigators, outcome assessors
nor the participants are aware of the treatment being
received, and therefore this represents a strong design
to minimise participant and investigator bias.2 Wider
members of the research team such as healthcare pro-
viders and statisticians may also be blinded to the des-
ignated allocation. Placebos are inert products which
enable researchers to compare treatments while consid-
ering the psychological effect associated with the per-
ception of a drug to provide a cure.3
Blinding the medication used for clinical trials to
ensure both the active and placebo drug match can
present many practical challenges, which unfortunately
can be underestimated and potentially impact on the
successful delivery of the study.4 When considering the
specifications of a placebo, the various characteristics
of the product must be identical to the medication
under investigation, and difficulties in sourcing ade-
quate placebos without collaboration of pharmaceuti-
cal companies have been reported previously.5
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Identical packaging and labelling are also necessary
and present their own challenges in relation to the
time required to repackage a medication, associated
costs and the stability of the product.4 As highlighted
by Wan et al.,4 the reporting of blinding procedures is
often incomplete or missing despite being included in
the Consolidated Standards of Reporting Trials
(CONSORT) statement; and while the impact of inad-
equate blinding may vary between studies, adequate
blinding cannot be assumed when such details are
absent from published materials.
Descriptions of blinding in published articles can
vary significantly, and Schulz and Grimes6 discussed
how many articles do not contain adequate reporting,
and therefore the reduction of bias often associated
with blinding should be judged by the individual
reader. Previously published literature appears to sug-
gest that there are inconsistencies when reporting the
descriptions of blinded medication, and Fergusson
et al.7 stress the need for trialists and journals to rou-
tinely report the methods of blinding. It is therefore
important to understand the prevalence and scope of
placebo medication descriptors being included. Our
review aimed to assess the reporting quality of blinding
descriptions for randomised clinical trials involving a
placebo medication treatment, and review how these
differ across three high impact medical journals, to
determine if authors and publishers are including this
level of detail in recently published manuscripts.
Methods
Three high impact medical journals (the Journal of the
American Medical Association (JAMA); the Lancet
and the New England Journal of Medicine (NEJM))8
were searched for randomised clinical trials, published
between April 2016 and March 2017, and 117 papers
involving a placebo medication treatment were
extracted. The authors consider the journals included
in the review to be of the highest impact and therefore
setting the standard for following reporting guidelines.
While the journals selected may not be an entirely rep-
resentative sample, it would not be possible to include
all journals that report randomised trials within the
confines of this review. Characteristics used to describe
the medication blinding were classified into the
following categories: ‘matching placebo’ or similar
phrase, appearance, packaging, labelling, smell,
colour, taste, texture, contents of placebo, volume and
none described.
At least two people were independently involved in
the data extraction and checking process, with any dis-
crepancies resolved through discussion with a third
party. All data were recorded in an electronic spread-
sheet (Microsoft Excel 2016).
Results
One hundred and seventeen articles regarding clinical
trials involving a placebo medication treatment were
published during the review period. Of these, 56 were
from the NEJM, 35 were from the Lancet and 26
were from the JAMA.
Publications reporting characteristics of placebo
treatments
Approximately three quarters of the articles published
during the review period reported at least one charac-
teristic of the placebo treatment, and therefore one
quarter did not provide this level of detail (Table 1).
The Lancet and the JAMA consistently had this infor-
mation present within the articles they accepted (89%
and 85%, respectively); however, articles published
within the NEJM only included this in approximately
half of their clinical trials involving a placebo medica-
tion treatment (57%).
Reported characteristics of the placebo treatment
Within the 117 articles found during the review, there
were 134 descriptions of characteristics for the placebo
medication treatments, indicating that some articles
included more than one descriptor. As shown in
Table 2, the most common characteristic was the use
of the phrase ‘matching placebo’ or similar (such as
‘identical placebo’) (38%), followed by contents of
the placebo (17%), packaging (16%) and appearance
(12%). Texture, taste and smell were the least reported
characteristics (1%, 2% and 3%, respectively).
Articles published within JAMA most frequently
reported on the contents of the placebo (31%) and
appearance (23%), while articles within the Lancet










At least one placebo characteristic reported 32 (57%) 31 (89%) 22 (85%) 85 (73%)
No placebo characteristics reported 24 (43%) 4 (11%) 4 (15%) 32 (27%)
NEJM: New England Journal of Medicine; JAMA: Journal of the American Medical Association.
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focussed on descriptions of the packaging (29%), and
articles with the NEJM described the contents of pla-
cebo and packaging most commonly (11% for each).
The individual characteristics of the placebo medica-
tion treatment varied across the journals, although
remained with similar proportions for labelling,
colour, smell, taste and texture; the least frequently
described features.
Publications reporting characteristics of placebo
treatments in relation to commercial or
non-commercial funding support
As shown in Table 3, 77 out of 116 articles were sup-
ported by commercial funding (66%). Across all jour-
nals, 48 (62%) articles reported at least one
characteristic of the placebo treatment and 29 (38%)
did not describe any. Most articles published within the
Lancet and the JAMA that were supported by com-
mercial funding reported at least one characteristic of
the placebo treatment (85% and 75%, respectively),
compared to only half of the articles within the
NEJM (44%).
Of the 39 studies not supported by commercial fund-
ing (34%), most articles across all of the journals
reported at least one characteristic of the placebo treat-
ment (95%). Only one article did not declare its fund-
ing source, and in this instance no characteristics of the
placebo treatment were reported.
Discussion
Main findings
Three quarters of the articles published during the
review period reported at least one characteristic of
the placebo treatment, suggesting that authors and/or
journals recognise the benefits of including this level of
detail within publications. However, with one quarter of
articles not including this information, this indicates
that there are still efforts to be made to ensure authors
and journals are aware of the importance of including a
detailed description of the placebo treatment, and that
adequate blinding cannot be assumed. While articles
within the Lancet and the JAMA consistently included
at least one characteristic of the placebo treatment, only
half of those in the NEJM did so. While the three jour-
nals with articles involved in this review all request that
authors conform to the CONSORT guidelines, the
Lancet specifically requests that all reports of
Table 2. Number and percentage of reported characteristics of placebo treatments.









Matching placebo (or similar phrase) 19 (34%) 14 (40%) 11 (42%) 44 (38%)
Contents of placebo 6 (11%) 6 (17%) 8 (31%) 20 (17%)
Packaging 6 (11%) 10 (29%) 3 (12%) 19 (16%)
Appearance 3 (5%) 5 (14%) 6 (23%) 14 (12%)
Volume 5 (9%) 6 (17%) 1 (4%) 12 (10%)
Labelling 4 (7%) 4 (11%) 2 (8%) 10 (9%)
Colour 3 (5%) 4 (11%) 1 (4%) 8 (7%)
Smell 1 (2%) 1 (3%) 2 (8%) 4 (3%)
Taste 1 (2%) 0 (0%) 1 (4%) 2 (2%)
Texture 1 (2%) 0 (0%) 0 (0%) 1 (1%)
NEJM: New England Journal of Medicine; JAMA: Journal of the American Medical Association.











Supported by commercial funding 39 (100%) 26 (100%) 12 (100%) 77 (100%)
At least one placebo characteristic reported 17 (44%) 22 (85%) 9 (75%) 48 (62%)
No placebo characteristics reported 22 (56%) 4 (15%) 3 (25%) 29 (38%)
Not supported by commercial funding 16 (100%) 9 (100%) 14 (100%) 39 (100%)
At least one placebo characteristic reported 15 (94%) 9 (100%) 13 (93%) 37 (95%)
No placebo characteristics reported 1 (6%) 0 (0%) 1 (7%) 2 (5%)
aThe publication with an unknown funding source has not been included.
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randomised trials include a section entitled
‘Randomisation and masking’ within their Methods.
The Lancet had the highest number of articles reporting
at least one characteristic of the placebo treatment, and
the journal guidelines described may contribute to this
detailed level of reporting. Other journals may also ben-
efit from revising their author guidelines to advise
researchers to include this level of detail in their articles.
Use of ‘matching placebo’ or a similar phrase was
most popular within the reviewed articles across the
NEJM, the Lancet and the JAMA; however, with such
encompassing terminology, it is difficult to understand
if those involved in the research have considered all of
the individual elements that must be examined to ensure
successful blinding. Work by Desbiens9 describes how
researchers usually trust that the placebo obtained from
drug companies is identical, and therefore successful
blinding has been achieved. However, Boutron et al.10
describe how a study investigating treatment with zinc
for the common cold failed due to its distinctive taste.
Researchers would therefore be wise to consider seeking
confirmation from those involved in the manufacturing
process, that the placebo characteristics match those of
the active treatment, and therefore the investigational
products are truly blinded. Within our review, descrip-
tions involving the contents of a placebo, its packaging
and appearance weremost commonly used after ‘match-
ing placebo’ or a similar phrase; however, their use was
inconsistent across the journals reviewed, suggesting
that author guidelines across journals do not consistent-
ly request this level of detail. Those features not involv-
ing appearance, such as smell, taste and texture
appeared least within the reviewed articles, indicating
that the matching of these to the active treatment is
rarely recorded within published materials. This level
of information provides absolute clarity if included in
a publication and therefore may avoid the inadequate
reporting of blinding, which can result in a negative per-
ception of the integrity of the research findings.
Fergusson et al.7 assessed the reporting of placebo
controlled trials published in five top medical journals
(including the BMJ, the JAMA, the Lancet, the Annals
of Internal Medicine and the NEJM) and four top psy-
chiatry journals. They found that 53% of the general
medical journals reported matching characteristics of
the placebo and intervention, with appearance and
taste most commonly reported. Interestingly, one of
the trials reported the dissimilarity between the placebo
and intervention. In comparison, only 32% of the psy-
chiatry journals reviewed reported the matching char-
acteristics between intervention and placebo. Again,
appearance was most often reported. Fergusson
et al.7 also highlight that several of the trials across
both journal categories did not report the type of pla-
cebo used. In comparison, our review found that 73%
of articles reported at least one placebo characteristic,
with use of ‘matching placebo’ or a similar phrase
being most prevalent (38%). While Fergusson et al.7
found appearance and taste to be most commonly
described, we found that these characteristics featured
less than others (12% and 2%, respectively), such as
the contents of the placebo (17%) and its packaging
(16%). Our review has revealed inconsistencies that
researchers should aim to minimise in order to improve
reporting quality.
Our review included 117 articles, two-thirds of
which were supported by commercial funding. Sixty-
two percent of those with commercial funding reported
at least one characteristic of the placebo treatment, in
comparison to 95% of articles without commercial
support. Within the context of this review, the findings
suggest that non-commercial researchers appear to be
more diligent in ensuring the characteristics of the pla-
cebo are included within their publications; however, it
must be considered that there were fewer non-
commercial articles published during the review
period. The findings may be due to commercially
funded studies utilising Interactive Response
Technology systems and central dispensing to address
their blinding requirements, compared to non-
commercial studies which may rely on academics famil-
iar with the written requirements necessary to record
the methodological aspects of blinding and reporting.
Blinding is included in the ‘CONSORT 2010 check-
list of information to include when reporting a rando-
mised trial’ recommending that authors specify ‘If
done, who was blinded after assignment to interven-
tions (for example, participants, care providers, those
assessing outcomes) and how’ and ‘If relevant, descrip-
tion of the similarity of interventions’. The CONSORT
statement suggests that such characteristics include the
appearance, taste, smell and method of administra-
tion.11 In a systematic review of 819 articles published
in high impact-factor journals, Boutron et al.10 found
insufficient reporting of the methods of blinding and
therefore suggested a need to increase the requirement
related to blinding issues in the CONSORT statements.
Journals and authors would benefit from ensuring
closer compliance with the guidelines to enable report-
ing to be standardised. Previously, CONSORT guide-
lines included an additional level of detail, requesting
that authors include ‘how the success of blinding
(masking) was assessed’; however, this has since been
removed due to a lack of empirical evidence and con-
cerns regarding the validity of assessing this aspect.12
Limitations
The review involved searching the main articles pub-
lished by researchers and did not include the review of
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any supplementary materials, such as protocols or sup-
plementary appendices, as these were not consistently
available. It is possible that the detailed blinding
descriptions were within these documents; however, it
must be considered how the main publication is often
the key source of the data for readers, and therefore the
most commonly utilised.
The review did not consider all possible blinding
techniques that researchers may employ, such as
achieving blinding by using two separate teams (such
as a blinded and unblinded nurse) for treatment admin-
istration and follow-up. We also did not evaluate the
differences in the intervention type (e.g. tablet, liquid)
or administration route (e.g. oral, intravenous) in rela-
tion to level of blinding detailed, and we anticipate
there may be some differences both in relation to
level of blinding achieved and reported.
Further research
Future research should focus on investigating the rea-
sons for inadequate recording of blinding descriptions,
with the aim of reducing the inconsistencies observed
and improving reporting. Should reporting guidelines
be amended in relation to blinding at any point, it
would be beneficial to evaluate the impact of this.
Conclusions
The findings of our review highlight that efforts are
being made to include descriptions of blinded medica-
tion within publications; however, there are inconsis-
tencies in reporting which suggests that guidelines are
not consistently being followed by the authors and
journals involved in the review process. In the context
of this review, it is not possible to determine the impact
of adherence to the CONSORT guidelines. The incon-
sistencies observed suggest that more can be done to
improve the reporting of medication blinding in rand-
omised trials, particularly with frequent use of ‘match-
ing placebo’ or a similar phrase, which does not
provide definitive proof that all elements of blinding
have been considered and successfully executed.
Whilst the number of words allocated for journal
articles is limited, authors should be keen to abide by
the CONSORT guidelines and include a succinct
description of blinding activity to avoid uncertainty
in their methods and potential misinterpretation of
research findings.
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